Image_7_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Table_2_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_1_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_8_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_4_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_6_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_2_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_9_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Image_3_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Table_1_Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With... by Yoon Ji Kim (136886)

“…In patients with T1D, insulin+sotagliflozin decreased the HbA1c level, daily insulin dose, and body weight without hypoglycemia compared with insulin monotherapy. …”

Cell viability in HepG2 cells: HepG2 cells were pre-treated with lovastatin for 24h before everolimus was added, and the combination of both drugs was incubated for 48h (A) or 120h... by Svenja Nölting (566453)

“…(A) Treatment with 5–20 μM lovastatin or with 10 nM everolimus alone significantly decreased HepG2 cell viability. …”

<b>Impact of the newly compiled Tai Chi (BaFa WuBu) on vascular health in middle-aged and older postmenopausal women: an analysis of the long-term intervention effect of a 24-week... by Haojie Li (14132931)

S1 File - by Berhan Tekeba (15353895)

“…We included a total weighted sample of 74,871 reproductive-aged women who gave birth in the five years preceding the survey. …”

<i>skn-1b</i> is not required for WT or <i>daf-2</i> longevity A-F) Survival of WT and <i>skn-1b</i> mutants in the absence and presence of <i>daf-2</i> mutation. by Nikolaos Tataridas-Pallas (10231350)

“…We conclude that <i>skn-1b</i> does not contribute to <i>daf-2</i> longevity. In a total of 15 trials (13 on OP50, 2 on HT115) bacteria we observed a slight decrease in <i>skn-1b</i> longevity compared to WT in 4 trials (<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1009358#pgen.1009358.s004" target="_blank">S4</a> and <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1009358#pgen.1009358.s005" target="_blank">S5</a> Tables). …”

Table_1_Cashew nut (Anacardium occidentale L.) and cashew nut oil reduce cardiovascular risk factors in adults on weight-loss treatment: a randomized controlled three-arm trial (Br... by Talitha Silva Meneguelli (18885979)

Image_1_Cashew nut (Anacardium occidentale L.) and cashew nut oil reduce cardiovascular risk factors in adults on weight-loss treatment: a randomized controlled three-arm trial (Br... by Talitha Silva Meneguelli (18885979)

Data Sheet 1_Dietary risk factors and cancer mortality burden from 1990 to 2021: a comparative study of China and global regions with varying sociodemographic development levels ba... by Chunxiu Zhao (21650204)

Supplementary Figure S8 from Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (... by Joshua Tobias (19663810)

Main effect neural results for participants with autism spectrum disorder (ASD) during real eye contact with ADOS-2 (Autism Diagnostic Observation Schedule, 2^nd edition)... by Joy Hirsch (12408)

“…</b> Blue colors indicate a negative relationship between neural responses and ADOS scores indicating that as symptom severity increases, neural responsiveness in these regions decreases. …”

Table_1_Association of Elevated Plasma FGF21 and Activated FGF21 Signaling in Visceral White Adipose Tissue and Improved Insulin Sensitivity in Gestational Diabetes Mellitus Subtyp... by Ning Wang (108353)

“…Elevated circulating FGF21 concentration at delivery, increased FGF receptor 1c and decreased klotho beta gene expression, enhanced ERK1/2 phosphorylation, and increased GLUT1, IR-B, PPAR-γ gene expression in vWAT were found in the GDM-resistance group as compared with the NGT group. …”